No, Secukinumab Cannot Be Initiated with Monthly Dosing Alone for Plaque Psoriasis
The weekly loading dose regimen (300 mg at weeks 0,1,2,3, and 4) is essential for optimal efficacy and should not be skipped, even for patients living abroad. Omitting the loading phase results in significantly inferior short-term outcomes and higher rates of primary treatment failure.
Evidence-Based Dosing Requirements
Standard FDA-Approved Regimen
The established dosing for plaque psoriasis is 1:
- Loading phase: 300 mg subcutaneous at weeks 0,1,2,3, and 4
- Maintenance phase: 300 mg every 4 weeks thereafter
This regimen carries a Strength A recommendation from the 2019 AAD-NPF Guidelines 2.
Clinical Consequences of Skipping Loading Doses
A 2020 real-world study directly compared outcomes with and without the loading regimen 3:
At Week 8:
- With loading: 60% achieved PASI 75
- Without loading: 40% achieved PASI 75 (p < 0.01)
At Week 12:
- With loading: 72% achieved PASI 75
- Without loading: 61% achieved PASI 75 (p < 0.01)
Critical finding: 25% of patients receiving secukinumab without loading doses discontinued due to primary inefficacy versus only 13% with standard dosing (p < 0.05). This risk was particularly pronounced in patients weighing >80 kg 3.
While efficacy eventually converged by week 16, the initial inferior response and higher discontinuation rate make this approach clinically problematic.
Practical Solutions for Patients Living Abroad
Option 1: Supervised Loading Phase Before Departure
- Administer all 5 loading doses (weeks 0-4) before the patient travels
- Patient can then self-administer monthly maintenance doses abroad
- This ensures optimal therapeutic response and minimizes treatment failure risk
Option 2: Arrange Local Administration
- Coordinate with healthcare providers in the patient's destination country
- Many biologics are available internationally with similar formulations
- Ensures proper loading regimen completion
Option 3: Extended Visit for Loading Phase
- Patient remains in your care for the 4-week loading period
- Provides monitoring for adverse events during the critical induction phase
- Allows assessment of early response before departure
Why the Loading Regimen Matters
The pharmacokinetic rationale is clear: secukinumab requires rapid achievement of therapeutic serum concentrations to effectively neutralize IL-17A in psoriatic lesions 1. The weekly loading schedule:
- Achieves steady-state concentrations faster
- Provides consistent drug exposure during the critical induction period
- Reduces the window for disease progression and patient discouragement
The maintenance dose alone (every 4 weeks) was specifically designed for patients who have already achieved therapeutic levels through loading 1.
Common Pitfall to Avoid
Do not rationalize skipping the loading phase based on convenience or cost considerations. The 2019 guidelines explicitly state that "the necessity of repeating the loading doses depends on disease severity and the number of doses missed" and recommend "repeating loading doses upon restarting administration if the patient is flaring and/or if more than 3-4 half-lives have passed since the previous dose" 2. This guidance underscores that loading doses are not optional—they are integral to treatment success.
Alternative Consideration
If the patient absolutely cannot accommodate the loading schedule, consider ustekinumab instead, which has a simpler dosing regimen (weeks 0,4, then every 12 weeks) that may be more compatible with international travel 2.